Defined Health becomes Cello Health BioConsulting

We are pleased to announce today, that Defined Health, our leading business development strategy consulting firm with a particular focus in early stage biotech has changed its name to Cello Health BioConsulting. The name change reflects the increased alignment of scientific, strategic and consulting experience that has taken place since Defined Health became part of Cello Health […]

More +

Register for free expert panel event at MassBio

Cello Health are pleased to be hosting a free expert panel discussion and lunch. REGISTER HERE: https://cellohealth.eventbrite.com Accelerated Early Drug Development: Compressing the Timeline from Clinical to Commercial  The age of advanced therapeutics (eg, gene therapy, orphan, etc) is characterized by accelerated development programs for personal/targeted medicines. An increased focus on smaller, more well-defined patient populations […]

More +

Cello Health announces acquisition of Healthcare team at Firstlight PR

We are pleased to announce today, Cello Health Communications has strengthened its business offer with the acquisition of the Healthcare team at Firstlight Public Relations. Firstlight’s Healthcare team was established in 2011 by Managing Director Pat Pearson, delivering communications for UK and International clients across the pharmaceutical and medical technology sectors. The team will be […]

More +

Welcome Jo Taylor to Cello Health Communications

We are pleased to announce today, Jo Taylor, formerly Senior Director of Corporate Communications, EMEA at Astellas has taken up the position of Head of Corporate Affairs at Cello Health Communications Europe. Featured in this year’s PR Week PowerBook, Jo has worked in senior leadership roles within communications for global pharma companies for over 25 […]

More +

Cello Health exhibiting at BIO-Europe 2018

Cello Health are pleased to announce our presence BIO-Europe’s Fall event on November 5 –7, 2018 in Copenhagen. Stop by booth #91 to speak to one of our team about our capabilities and experience in supporting BioPharm clients from asset identification or acquisition through to informing the Phase 3 programme. In addition to our booth presence, […]

More +